Evidence map›Paper›PMID 41455693›Full record

ArticleBlood cancer journal2025

Impact of t(11;14) primary cytogenetic abnormality and the cumulative effect of multiple high-risk cytogenetics at diagnosis on the outcomes of patients with primary plasma cell leukemia.

Tamer Hellou, Shaji K Kumar, Samhar Samer Alouch, Adrian Almodovar-Diaz, Angela Dispenzieri, Dragan Jevremovic, Francis K Buadi, David Dingli, Saurabh Zanwar, Suzanne R Hayman and 18 more

Abstract readLetter
In one paragraph

Article in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Tamer HellouDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0009-0009-2179-3963
Shaji K KumarDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-5392-9284
Samhar Samer AlouchDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0009-0009-2697-2215
Adrian Almodovar-DiazDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Angela DispenzieriDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-8780-9512
Dragan JevremovicDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-1792-5822
Francis K BuadiDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0003-3214-0203
David DingliDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-7477-3004
Saurabh ZanwarDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-5074-8453
Suzanne R HaymanDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Prashant KapoorDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-4342-364X
Nelson LeungDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Amie FonderDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Miriam HobbsDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Yi Lisa HwaDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Eli MuchtarDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0003-2210-2174
Rahma WarsameDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Taxiarchis V KourelisDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-8573-9434
Joselle CookDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-5335-9533
Moritz BinderDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-9014-9658
Nadine AbdallahDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-9195-1589
Yi LinDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-1556-6416
Ronald S GoDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-8284-3495
Mustaqeem A SiddiquiDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-4640-7311
Robert A KyleDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Morie A GertzDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-3853-5196
S Vincent RajkumarDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-5862-1833
Wilson I GonsalvesDivision of Hematology, Mayo Clinic, Rochester, MN, USA. gonsalves.wilson@mayo.edu.ORCID http://orcid.org/0000-0001-6890-969X

Funding

Mayo Clinic Center for Clinical ProteomicsU01CA271410 · NCI · MAYO CLINIC ROCHESTER · PI Rafael Fonseca, AKHILESH PANDEY · 2022 to 2026
$5.3M
Assessment of Metabolites Among Asymptomatic Precursor and Malignant Monoclonal GammopathiesR01CA254961 · NCI · MAYO CLINIC ROCHESTER · PI GONSALVES, WILSON · 2021 to 2024
$1.5M
NCI NIH HHS R01 CA254961NCI NIH HHS U01 CA271410
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41455693
PMCPMC12743652

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.